quantisnow
FeedTopReportsPricing
⌘K
Live feed
16:30:27·156d
INSIDERFiling
First Advantage Corporation logo

Chief Legal Officer Jardine Bret T converted options into 1,365 shares, covered exercise/tax liability with 411 shares and sold $12,526 worth of shares (954 units at $13.13) (SEC Form 4)

FA· First Advantage Corporation
Technology
Original source

Companies

  • FA
    First Advantage Corporation
    Technology

Recent analyst ratings

  • Mar 6UpdateBarclays$15.00
  • May 9UpdateRBC Capital Mkts$20.00
  • Apr 10UpdateBarclays$15.00
  • Dec 11UpdateBMO Capital Markets$20.00
  • Nov 20UpdateBarclays$22.00
  • Nov 15UpdateRBC Capital Mkts$22.00

Related

  • PR7d
    First Advantage to Release First Quarter 2026 Financial Results and Hold Investor Conference Call on May 7, 2026
  • INSIDER41d
    Global Chief Operating Officer Nairne Douglas converted options into 742 shares, increasing direct ownership by 3% to 22,457 units (SEC Form 4)
  • PR42d
    First Advantage Releases 2026 Global Trends Report: Priorities and Outlook from HR Leaders and Job Seekers
  • INSIDER48d
    Global Chief Operating Officer Nairne Douglas converted options into 743 shares, increasing direct ownership by 2% to 46,742 units (SEC Form 4)
  • INSIDER48d
    Chief Legal Officer Jardine Bret T sold $20,683 worth of shares (1,690 units at $12.24), converted options into 929 shares and covered exercise/tax liability with 329 shares, decreasing direct ownership by 13% to 7,008 units (SEC Form 4)
  • ANALYST49d
    First Advantage Corp. upgraded by Barclays with a new price target
  • INSIDER50d
    Chief Legal Officer Jardine Bret T converted options into 1,686 shares and covered exercise/tax liability with 596 shares, increasing direct ownership by 16% to 8,098 units (SEC Form 4)
  • INSIDER50d
    SEC Form 4 filed by Chief Financial Officer Marks Steven Irwin
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022